NASDAQ: PTPIPetros Pharmaceuticals Inc Stock
$0.04+0.00 (+0%)
Updated Apr 17, 2025
PTPI Price
$0.04
Fair Value Price
N/A
Market Cap
$2.19M
52 Week Low
$0.04
52 Week High
$0.77
P/E
-0.01x
P/B
-0.29x
P/S
0.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.11M
Earnings
-$14.32M
Gross Margin
76.3%
Operating Margin
-269.13%
Profit Margin
-524.2%
Debt to Equity
-2.42
Operating Cash Flow
-$3M
Beta
1.07
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PTPI Overview
Petros Pharmaceuticals, Inc. develops and commercializes therapeutics for men's health issues (erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders). lt markets its own line of ED products in the form of vacuum erection devices through its subsidiary, Timm Medical, Inc. Petros Pharmaceuticals was founded in 2020 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PTPI's potential to beat the market
- PTPI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
PTPI
RankedUnranked of 54
RankedUnranked of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $24.65 | A | |
| $13.76 | A |
Be the first to know about important PTPI news, forecast changes, insider trades & much more!
PTPI News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PTPI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTPI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PTPI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PTPI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PTPI due diligence checks available for Premium users.
Valuation
PTPI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
20.48x
Market
27.98x
PTPI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.29x
Industry
1.99x
PTPI's financial health
Profit margin
Revenue
$725.4k
Net Income
-$9.3M
Profit Margin
-1,487.3%
PTPI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PTPI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.6M
Liabilities
$18.1M
Debt to equity
-2.42
PTPI's short-term liabilities ($18.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTPI's short-term assets ($7.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTPI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTPI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$965.4k
Investing
-$5.4k
Financing
-$1.1M
PTPI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PTPI vs Pharmaceutical Stocks
Petros Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.